作为疾病中蛋白质构成和组合的调节器的N-糖化
Chiranjeevi Pasala1, Sahil Sharma1, Tanaya Roychowdhury1
1Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Biomolecules
|March 28, 2024
概括
糖化,即甘氨酸与蛋白质的结合,影响蛋白质的形状和功能. 异常的糖化可以导致癌症和神经退行性疾病等疾病,提供治疗点.
科学领域:
- 生物化学和分子生物学
- 葡萄糖生物学 葡萄糖生物学
- 疾病的病原发生 疾病的病原发生
背景情况:
- 糖基化是一种关键的翻译后修饰,调节细胞功能.
- 改变的糖化模式与许多疾病有关,包括癌症和感染.
- N-甘氨酸对蛋白质构成和蛋白质组件的形成有显著影响.
研究的目的:
- 审查N-糖化在蛋白质构成和疾病中的作用.
- 探索N-甘氨酸如何影响健康和疾病中的蛋白质相互作用和组合.
- 突出针对糖基化介导的构造变化的治疗含义.
主要方法:
- 文献综述侧重于N-糖化对蛋白质结构的影响.
- 分析了包括SARS病毒尖端蛋白,蛋白和GRP94.4.在内的例子.
- 讨论糖体,蛋白质构成和疾病病理学之间的联系.
主要成果:
- N-glycans批判性地选择蛋白质构成,并影响病原蛋白质组件的形成.
- 这些例子展示了N-糖化如何能够推动从生理性转变为与疾病相关的蛋白质形式的过程.
- 了解这些机制,可以了解疾病的发展和潜在的治疗方法.
结论:
- N-糖化是蛋白质构成和组合的关键调节剂,直接影响疾病.
- 针对异常的糖化和由此产生的蛋白质结构变化提供了有前途的治疗策略.
- 这篇评论弥合了对糖体,蛋白质结构和疾病发病的理解.
相关概念视频
Protein Glycosylation
6.9K
Glycosylation, the most common post-translational modification for proteins, serves diverse functions. Adding sugars to proteins makes the proteins more resistant to proteolytic digestion. Glycosylated proteins can act as markers and receptors to promote cell-cell adhesion. Additionally, they have many essential quality control functions in the cell, such as correct protein folding and facilitating transport of misfolded proteins to the cytosol, which can be degraded.
Glycosylation occurs in...
Glycosylation occurs in...
6.9K
Oligosaccharide Assembly
2.8K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.8K
Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
Protein Folding Quality Check in the RER
3.7K
ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
3.7K
Protein Modifications in the RER
5.2K
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
5.2K
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


